The biobanking market - valued at $60.74 billion in 2022 - is forecast to expand at a compound annual growth rate (CAGR) of 5.68%, reaching a market size of $89.41 billion by 2029.
So says the Biobanking Market - Forecasts from 2024 to 2029 report from ResearchAndMarkets.com.
According to the report, the field is being driven by significant investments in the research and development of advanced therapeutics including personalized medicine, regenerative medicine and cancer genomic investigations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze